Asia Pacific Diabetes Drugs Maret Forecast 2019-2027

KEY FINDINGS

The CAGR for the Asia Pacific diabetes drugs market is expected to be 10.82% for the forecast period of 2019-2027. Economic development and rise in healthcare spending are expected to increase the demand for diabetes drugs further. Despite a large number of people with diabetes in the region, awareness is still low, and therefore the situation needs to be addressed.

MARKET INSIGHTS

Diabetes is associated with a myriad of complications which affect the feet, eyes, kidneys, and cardiovascular health. Nearly half of people with diabetes remain undetected, accounting for complications at the time of diagnosis. Screening can differentiate an asymptomatic individual at high risk from one at low risk for diabetes. Another reason attributed to the increase in the prevalence of diabetes can possibly be the increase in dietary fat and protein consumption, as well as the expanding elderly population.

COMPETITIVE INSIGHTS

Prominent players in the Asia Pacific diabetes drugs market are Eli Lilly And Company, Astellas Pharma, B.Braun Melsungen Ag, Novo Nordisk A/S, Diavacs Inc., Sanofi, Astrazeneca Plc., Albireo Pharma Inc. Macrogenics, Inc., Xoma Corp., Glaxosmithkline, Xeris Pharmaceuticals, Merck and Pfizer.

Table of Contents

1. RESEARCH SCOPE

• 1.1. STUDY GOALS
• 1.2. SCOPE OF THE MARKET STUDY
• 1.3. WHO WILL FIND THIS REPORT USEFUL?
• 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

• 2.1. SOURCES OF DATA
• 2.1.1. SECONDARY DATA
• 2.1.2. PRIMARY DATA
• 2.2. TOP-DOWN APPROACH
• 2.3. BOTTOM-UP APPROACH
• 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

• 3.1. MARKET SUMMARY
• 3.2. KEY FINDINGS
• 3.2.1. RISING PREVALENCE OF TYPE 2 DIABETES
• 3.2.2. INSULIN MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE

4. MARKET DETERMINANTS

• 4.1. MARKET DRIVERS
• 4.1.1. INCREASE IN PREVALENCE OF DIABETES
• 4.1.2. ADVANCES IN INSULIN TECHNOLOGY
• 4.1.3. GROWING ELDERLY POPULATION
• 4.2. MARKET RESTRAINTS
• 4.2.1. LACK OF AWARENESS AMONG PEOPLE
• 4.2.2. COST SENSITIVITY ISSUES
• 4.3. MARKET OPPORTUNITIES
• 4.3.1. DEVELOPMENT OF NEW FORMULATIONS
• 4.3.2. INCREASING RESEARCH AND DEVELOPMENT
• 4.4. MARKET CHALLENGES
• 4.4.1. FIERCE MARKET COMPETITION
• 4.4.2. RISING CONCERNS IN SCIENTIFIC COMMUNITY
• 4.4.3. GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
• 4.4.4. POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN

5. MARKET SEGMENTATION

• 5.1. MARKET BY DIABETES TYPE 2019-2027
• 5.1.1. TYPE 1
• 5.1.2. TYPE 2
• 5.2. MARKET BY PRODUCT CLASS 2019-2027
• 5.2.1. INSULIN
• 5.2.1.1. FAST ACTING INSULIN
• 5.2.1.2. INTERMEDIATE ACTING INSULIN
• 5.2.1.3. LONG-ACTING INSULIN
• 5.2.2. NON-INSULIN
• 5.2.2.1. DPP-4 INHIBITOR
• 5.2.2.2. GLP-1 RECEPTORS AGONISTS
• 5.2.2.3. SGLT-2 INHIBITORS
• 5.2.2.4. OTHER NON-INSULIN DRUGS

6. KEY ANALYTICS

• 6.1. PORTER'S FIVE FORCE ANALYSIS
• 6.1.1. THREAT OF NEW ENTRANTS
• 6.1.2. THREAT OF SUBSTITUTE
• 6.1.3. BARGAINING POWER OF SUPPLIERS
• 6.1.4. BARGAINING POWER OF BUYERS
• 6.1.5. THREAT OF COMPETITIVE RIVALRY
• 6.2. OPPORTUNITY MATRIX
• 6.3. ETYMOLOGY OF DIABETES DRUGS MARKET
• 6.4. LEGAL, POLICY AND REGULATORY ISSUES

7. GEOGRAPHICAL ANALYSIS

• 7.1. ASIA-PACIFIC (APAC)
• 7.1.1. CHINA
• 7.1.2. INDIA
• 7.1.3. AUSTRALIA
• 7.1.4. JAPAN
• 7.1.5. SOUTH KOREA
• 7.1.6. INDONESIA
• 7.1.7. MALAYSIA
• 7.1.8. PHILIPPINES
• 7.1.9. THAILAND
• 7.1.10. VIET NAM
• 7.1.11. REST OF ASIA-PACIFIC (ROAPAC)

8. COMPANY PROFILES

• 8.1. ELI LILLY AND COMPANY
• 8.1.1. OVERVIEW
• 8.1.2. PRODUCTS PORTFOLIO
• 8.1.3. SWOT ANALYSIS
• 8.1.4. STRATEGIC INITIATIVES
• 8.2. ASTRAZENECA PLC.
• 8.2.1. OVERVIEW
• 8.2.2. PRODUCT PORTFOLIO
• 8.2.3. SWOT ANALYSIS
• 8.2.4. STRATEGIC INITIATIVES
• 8.3. B.BRAUN MELSUNGEN AG
• 8.3.1. OVERVIEW
• 8.3.2. PRODUCT PORTFOLIO
• 8.3.3. SCOT ANALYSIS
• 8.3.4. STRATEGIC ANALYSIS
• 8.4. NOVO NORDISK A/S
• 8.4.1. OVERVIEW
• 8.4.2. PRODUCTS PORTFOLIO
• 8.4.3. SWOT ANALYSIS
• 8.4.4. STRATEGIC INITIATIVES
• 8.5. SANOFI
• 8.5.1. OVERVIEW
• 8.5.2. PRODUCTS PORTFOLIO
• 8.5.3. SWOT ANALYSIS
• 8.5.4. STRATEGIC INITIATIVES
• 8.6. DIAVACS INC.
• 8.6.1. OVERVIEW
• 8.6.2. PRODUCT PORTFOLIO
• 8.6.3. SWOT ANALYSIS
• 8.7. XOMA CORP.
• 8.7.1. OVERVIEW
• 8.7.2. PRODUCT PORTFOLIO
• 8.7.3. SWOT ANALYSIS
• 8.7.4. STRATEGIC INITIATIVES
• 8.8. ALBIREO PHARMA INC.
• 8.8.1. OVERVIEW
• 8.8.2. PRODUCT PORTFOLIO
• 8.8.3. SWOT ANALYSIS
• 8.9. MACROGENICS, INC.
• 8.9.1. OVERVIEW
• 8.9.2. PRODUCT PORTFOLIO
• 8.9.3. SWOT ANALYSIS
• 8.10. ASTELLAS PHARMA
• 8.10.1. OVERVIEW
• 8.10.2. PRODUCT PORTFOLIO
• 8.10.3. SWOT ANALYSIS
• 8.10.4. STRATEGIC INITIATIVES
• 8.11. GLAXOSMITHKLINE
• 8.11.1. OVERVIEW
• 8.11.2. PRODUCT PORTFOLIO
• 8.11.3. SWOT ANALYSIS
• 8.12. MERCK
• 8.12.1. OVERVIEW
• 8.12.2. PRODUCT PORTFOLIO
• 8.12.3. SWOT ANALYSIS
• 8.12.4. STRATEGIC INITIATIVES
• 8.13. PFIZER
• 8.13.1. OVERVIEW
• 8.13.2. PRODUCT PORTFOLIO
• 8.13.3. SWOT ANALYSIS
• 8.13.4. STRATEGIC INITIATIVES
• 8.14. XERIS PHARMACEUTICALS
• 8.14.1. OVERVIEW
• 8.14.2. PRODUCT PORTFOLIO
• 8.14.3. SWOT ANALYSIS
• 8.14.4. STRATEGIC INITIATIVES

TABLE LIST

• TABLE 1 ASIA PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• TABLE 2 ASIA PACIFIC DIABETES DRUGS MARKET BY DIABETES TYPES 2019-2027, ($ MILLION)
• TABLE 3 ASIA PACIFIC DIABETES DRUGS MARKET IN TYPE 1 DIABETES 2019-2027 ($ MILLION)
• TABLE 4 ASIA PACIFIC DIABETES DRUGS MARKET IN TYPE 2 DIABETES 2019-2027 ($ MILLIONS)
• TABLE 5 ASIA PACIFIC DIABETES DRUGS MARKET BY PRODUCT CLASS 2019-2027 ($ MILLIONS)
• TABLE 6 ASIA PACIFIC DIABETES DRUGS MARKET IN INSULIN TYPE 2019-2027 ($ MILLION)
• TABLE 7 ASIA PACIFIC DIABETES DRUGS MARKET IN INSULIN BY TYPES 2019-2027 ($ MILLION)
• TABLE 8 ASIA PACIFIC INSULIN MARKET IN FAST ACTING INSULIN 2019-2027 ($ MILLION)
• TABLE 9 ASIA PACIFIC INSULIN MARKET IN INTERMEDIATE ACTING INSULIN 2019-2027 ($ MILLION)
• TABLE 10 ASIA PACIFIC INSULIN MARKET IN LONG ACTING INSULIN 2019-2027 ($ MILLION)
• TABLE 11 ASIA PACIFIC DIABETES DRUGS MARKET IN NON-INSULIN DRUGS 2019-2027 ($ MILLION)
• TABLE 12 ASIA PACIFIC DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY TYPES 2019-2027 ($ MILLION)
• TABLE 13 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN DPP-4 INHIBITOR 2019-2027 ($ MILLION)
• TABLE 14 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN GLP-1 RECEPTORS AGONISTS 2019-2027 ($ MILLION)
• TABLE 15 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN SGLT-2 INHIBITORS 2019-2027 ($ MILLION)
• TABLE 16 ASIA PACIFIC NON-INSULIN DRUGS MARKET IN OTHER NON-INSULIN DRUGS 2019-2027 ($ MILLION)
• TABLE 17 ASIA-PACIFIC DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

FIGURES LIST

• FIGURE 1 ASIA PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ BILLION)
• FIGURE 2 ASIA PACIFIC DIABETES DRUGS MARKET, BY TYPE 2 DIABETES 2019-2027 ($ MILLION)
• FIGURE 3 AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY GENDER (IN YEARS)
• FIGURE 4 PORTER'S FIVE FORCES ANALYSIS OF DIABETES DRUGS MARKET
• FIGURE 5 CHINA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 6 INDIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 7 AUSTRALIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 8 JAPAN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 9 SOUTH KOREA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 10 INDONESIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 11 MALAYSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 12 PHILIPPINES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 13 THAILAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 14 VIETNAM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
• FIGURE 15 REST OF ASIA-PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)